TrialFrontiers in neurology2026

Long-term safety, tolerability, and efficacy of subcutaneous efgartigimod PH20 in generalized myasthenia gravis: final results from a phase 3 open-label extension study (ADAPT-SC+).

Andreas Meisel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.